Importance: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. Objective: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation. Design, Setting, and Participants: In this prospective cohort study, 220 participants from outpatient practices were recruited at the US National Institutes of Health. A total of 115 consecutively recruited patients with psoriasis were followed up at 1 year. The study was conducted from January 1, 2013, through October 31, 2016, with data analyzed in November 2016. Exposure: Skin inflammation measured as Psoriasis Area and Severity Index (PASI) score. Main Outcomes and Measures: Vascular inflammation assessed as target-to-background ratio by 18fluorodeoxyglucose positron emission tomography/computed tomography. Results: Among the 115 patients, the mean (SD) age at 1-year follow-up was 50.8 (12.8) years and 68 were men (59%). The cohort had a low cardiovascular risk by Framingham risk score and mild-to-moderate psoriasis, with a median PASI score of 5.2 (interquartile range, 3.0-8.9). At follow-up, the total cohort had a median improvement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly anti-tumor necrosis factor) and phototherapy (15%) (P < .001). Moreover, improvement in PASI score was associated with improvement in target-to-background ratio of 6%, mainly driven by those with higher responses in PASI score (P < .001). This association persisted beyond traditional risk factors (β = 0.19; 95% CI, 0.012-0.375; P = .03) and was the strongest in those initiated with anti-tumor necrosis factor therapy (β = 0.79; 95% CI, 0.269-1.311; P = .03). Conclusions and Relevance: Improvement in psoriasis skin disease severity was associated with improvement in aortic vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography, with greater improvement in aortic vascular inflammation observed in those who had higher than 75% reduction in skin disease severity. These findings suggest that controlling remote target organ inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials are needed to confirm these findings.
Importance: Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect of treating inflammation in a target organ (eg, the skin) on vascular diseases. Objective: To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation. Design, Setting, and Participants: In this prospective cohort study, 220 participants from outpatient practices were recruited at the US National Institutes of Health. A total of 115 consecutively recruited patients with psoriasis were followed up at 1 year. The study was conducted from January 1, 2013, through October 31, 2016, with data analyzed in November 2016. Exposure: Skin inflammation measured as Psoriasis Area and Severity Index (PASI) score. Main Outcomes and Measures: Vascular inflammation assessed as target-to-background ratio by 18fluorodeoxyglucose positron emission tomography/computed tomography. Results: Among the 115 patients, the mean (SD) age at 1-year follow-up was 50.8 (12.8) years and 68 were men (59%). The cohort had a low cardiovascular risk by Framingham risk score and mild-to-moderate psoriasis, with a median PASI score of 5.2 (interquartile range, 3.0-8.9). At follow-up, the total cohort had a median improvement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly anti-tumor necrosis factor) and phototherapy (15%) (P < .001). Moreover, improvement in PASI score was associated with improvement in target-to-background ratio of 6%, mainly driven by those with higher responses in PASI score (P < .001). This association persisted beyond traditional risk factors (β = 0.19; 95% CI, 0.012-0.375; P = .03) and was the strongest in those initiated with anti-tumor necrosis factor therapy (β = 0.79; 95% CI, 0.269-1.311; P = .03). Conclusions and Relevance: Improvement in psoriasis skin disease severity was associated with improvement in aortic vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography, with greater improvement in aortic vascular inflammation observed in those who had higher than 75% reduction in skin disease severity. These findings suggest that controlling remote target organ inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials are needed to confirm these findings.
Authors: Amparo L Figueroa; Sharath S Subramanian; Ricardo C Cury; Quynh A Truong; Joseph A Gardecki; Guillermo J Tearney; Udo Hoffmann; Thomas J Brady; Ahmed Tawakol Journal: Circ Cardiovasc Imaging Date: 2011-10-28 Impact factor: 7.792
Authors: O Ahlehoff; G H Gislason; J Lindhardsen; J B Olesen; M Charlot; L Skov; C Torp-Pedersen; P R Hansen Journal: J Intern Med Date: 2011-03-24 Impact factor: 8.989
Authors: Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel Journal: J Invest Dermatol Date: 2009-05-21 Impact factor: 8.551
Authors: Su Jin Lee; Young Keun On; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Ahmed Tawakol; Zahi A Fayad; Robin Mogg; Achilles Alon; Michael T Klimas; Hayes Dansky; Sharath S Subramanian; Amr Abdelbaky; James H F Rudd; Michael E Farkouh; Irene O Nunes; Chan R Beals; Sudha S Shankar Journal: J Am Coll Cardiol Date: 2013-05-30 Impact factor: 24.094
Authors: Raphaël Duivenvoorden; Venkatesh Mani; Mark Woodward; David Kallend; Gabriela Suchankova; Valentin Fuster; James H F Rudd; Ahmed Tawakol; Michael E Farkouh; Zahi A Fayad Journal: JACC Cardiovasc Imaging Date: 2013-10
Authors: Michael S Garshick; Tessa J Barrett; Todd Wechter; Sarah Azarchi; Jose U Scher; Andrea Neimann; Stuart Katz; Judilyn Fuentes-Duculan; Maria V Cannizzaro; Sanja Jelic; Edward A Fisher; James G Krueger; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2019-04 Impact factor: 8.311
Authors: Martin P Playford; Amit K Dey; Claudia Zierold; Aditya A Joshi; Frank Blocki; Fabrizio Bonelli; Justin A Rodante; Charlotte L Harrington; Joshua P Rivers; Youssef A Elnabawi; Marcus Y Chen; Mark A Ahlman; Heather L Teague; Nehal N Mehta Journal: Atherosclerosis Date: 2019-08-17 Impact factor: 5.162
Authors: Nehal N Mehta; Daniel B Shin; Aditya A Joshi; Amit K Dey; April W Armstrong; Kristina Callis Duffin; Zelma Chiesa Fuxench; Charlotte L Harrington; Rebecca A Hubbard; Robert E Kalb; Alan Menter; Daniel J Rader; Muredach P Reilly; Eric L Simpson; Junko Takeshita; Drew A Torigian; Thomas J Werner; Andrea B Troxel; Stephen K Tyring; Suzette Baez Vanderbeek; Abby S Van Voorhees; Martin P Playford; Mark A Ahlman; Abass Alavi; Joel M Gelfand Journal: Circ Cardiovasc Imaging Date: 2018-06 Impact factor: 7.792
Authors: Joshua P Rivers; Tiffany M Powell-Wiley; Amit K Dey; Justin A Rodante; Jonathan H Chung; Aditya A Joshi; Balaji Natarajan; Aparna P Sajja; Abhishek Chaturvedi; Anshuma Rana; Charlotte L Harrington; Heather L Teague; Benjamin N Lockshin; Mark A Ahlman; Jianhua Yao; Martin P Playford; Joel M Gelfand; Nehal N Mehta Journal: JACC Cardiovasc Imaging Date: 2017-10-18
Authors: Milena Aksentijevich; Sundus S Lateef; Paula Anzenberg; Amit K Dey; Nehal N Mehta Journal: Trends Cardiovasc Med Date: 2019-11-20 Impact factor: 6.677